Welcome to the Precipio Incorporated Second Quarter 2019 Corporate Update Call for shareholders. [Operator Instructions]. Please note that the conference is being recorded. Statements made during this call contain forward looking statements about our business. You should not place undue reliance on forward looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms, similar meaning risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward looking statements include that are not limited to the matters listed under risk factors in our annual report on Form-10K for the year ended December 31, 2018 which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov, statements and information including forward-looking statements speak only to the date they are provided unless an earlier date is indicated. And we do not undertake any obligation to publicly update any statements or information, including forward looking statements, whether as a result of new information, future events or otherwise except as required by law. Now let me hand the conference over to Ilan, Precipio's CEO.

Okay, thank you very much. So good afternoon, everyone. Thank you for joining today's call. As always, thanks to those who send questions in advance, we'll do our best to address them. On our call today I'll provide an update on the business, Carl, Precipio's CFO will give a financial perspective and then I'll close with a few final remarks. Before I begin, I'd like to recognize Carl and his team for the company's successful filing a week in advance of the deadline of our recent 10Q. In the past, the combination of complicated transactions and subsequent complex financial statements, together with a relatively lean and small finance team, tasked with a company accomplishing a tonne of work resulted in us frequently filing for extensions as we came up to our two year mark since the merger Carl and his team set as a goal to file before the deadline and I was delighted to see the team meet that goal with flying colors. Two things led to this first, despite the team remaining lean we continuously got better and together with Marcum, our auditors we put in place processes to streamline the preparation and review of our financial statements by our auditors. Second, simply put, our financial statements got simpler call. Carl will discuss this in further detail in a few moments but if you look at our balance sheet for example, it tells a very different and far cleaner story than it did two years ago. So kudos to Carl and his team, job well done. Now onto the business performance, I'll cover both sides of our business, the product side and the pathology services side. Let me start with our technology services. As you saw from the recent financial results, as well as the news update we…

Thank you, Ilan for the introduction. Good afternoon. Let me extend a welcome to everyone on this shareholder call. I'm Carl Iberger, Precipio's Chief Financial Officer. On today's call, I will be bringing you up to date on significant transactions completed in 2019. Our operating performance and our balance sheet and what we need to accomplish to obtain breakeven operations. Let me start my discussion with addressing several material and significant items the company has concluded during Q2. When considering these items taken either individually or collectively, they have been a negative financial and resource drain on the company to-date. Getting these behind us will benefit our future. All of these items have been reported on in our 10-Q. First, as Precipio entered 2019 the company had two significant legal claims facing it. Both were holdovers from the 2017 merger. By the end of this past quarter, the company settled both investor related Transgenomic pre-merger matters. The first matter is Crede Capital claim on Transgenomic. As of May 2019, this matter has been settled and fully paid with its origin dating back to July 2015 settling and concluding the inherited liability obligations of Transgenomic to Crede Capital is a material financial weight lifted off the company. The second matter is a legal action stemming from Transgenomic activities pre-merger. Campbell et al. Transgenomic is a lawsuit. In June, negotiations were completed. All parties have agreed on a settlement. Final documents will be completed during Q3. All impact of the settlement have been accounted for in our second quarter financials. A third item non-legal but more contractual dealing with post-merger agreement was also settled, signed and completed in May of this year. This item has to do with Leviston Resources LLC. At the conclusion of Q2, Precipio has satisfied all outstanding obligations…

Thank you, Carl, for that detailed analysis. So a few final thoughts. Our team and I continue to work hard at building the company and achieving the goals we set out, and that we've promised to deliver on to you the shareholder. I know that many of you, myself included, are disappointed at the decline of the stock price where it was a few months ago post reverse split. Our stock has previously suffered from aggressive shorting but from examining the recent short positions around the stock, you can actually see a relatively low percentage of short interest and reduced short pressure, which is very positive. The volatility in our share price is probably a reflection of the perception and uncertainty in the eyes of fund in the market around the company's capabilities. In our view, this is not an indication of the company's performance, because from a revenue perspective and financial perspective, we've demonstrated relatively stable growth. We believe we have great prospects for our products, which are undergoing validation by institutions and these processes, as I mentioned, about to take some time but once they're completed, we believe that the results will have a dramatic impact on the company's finances as well as its overall position in the market as a global leader in providing impactful and valuable products that we've created. And with that, I believe that the stock volatility will stabilize and it will reach a price that reflects the value we deliver. We're all entirely dedicated to achieving this goal and with each day that goes by, with each meeting that takes place, we grow more and more confident in our value proposition, the clinical benefit to our customers and their patients and the subsequent direct financial value to our stockholders. Never has there been a more exciting and more important time to be where we are today. Cancer touches everyone and with the tools we've created no cancer patient should ever suffer the consequences of being misdiagnosed. I want to thank you all for your continued interest and the support of the company. And I look forward to speaking with you on our next call. Wishing everyone a nice evening. Thank you

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect. End of Q&A: